Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial

Overview of attention for article published in Critical Care, January 2023

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (93rd percentile)
Above-average Attention Score compared to outputs of the same age and source (62nd percentile)

Mentioned by

blogs: 2 blogs

twitter: 24 X users

Citations

dimensions_citation: 17 Dimensions

Readers on

mendeley: 39 Mendeley

Summary Blogs X Dimensions citations

So far, Altmetric has seen 2 posts from 2 blogs.

Baricitinib’s Effectiveness and Safety in Treating Hospitalized Adults with Severe COVID-19

Physician's Weekly, 06 Mar 2023

The following is the summary of “Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari…

Critical Care Evidence Updates – January 2023

The Bottom Line, 09 Feb 2023

What’s new in the Critical Care literature – monthly updates

This page shows the most recent blog posts that mention this research output.

Click here to find out how to access more activity.